Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nanocarriers possessing components with different rates of release

a technology of nanocarriers and components, applied in the field of synthetic nanocarriers, can solve the problems of insufficient information regarding the biological interplay between these two agents and the lack of control of their delivery, and achieve the effect of inducing or enhancing an immune respons

Inactive Publication Date: 2010-12-02
SELECTA BIOSCI
View PDF1 Cites 160 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0280]This experiment demonstrates that utilization of NC-Nic carrying R848 (a Th1 adjuvant, TLR7 / 8 agonist), which was released from NC-Nic much faster at physiological conditions (pH=4.5) than the antigen (PEG-nicotine), generates a strong and long-term humoral immune response against NC-carried antigen. Antibody induction after immunization with NC-Nic (nanocarrier exhibiting nicotine on the outer surface in the form of PLA-PEG-nicotine) also carrying adjuvant R848.

Problems solved by technology

However, information regarding the biological interplay between these two agents and how the control of their delivery can provide for optimal in vivo effects is lacking.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nanocarriers possessing components with different rates of release
  • Nanocarriers possessing components with different rates of release
  • Nanocarriers possessing components with different rates of release

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Activated Polymer

[0133]PLA (dl-polylactide) (Resomer R202H from Boehringer-Ingelheim, KOH equivalent acid number of 0.21 mmol / g, intrinsic viscosity (iv): 0.21 dl / g) (10 g, 2.1 mmol, 1.0 eq) was dissolved in dichloromethane (DCM) (35 mL). EDC (2.0 g, 10.5 mmol, 5 eq) and NHS (1.2 g, 10.5 mmol, 5 eq) were added. The solids were dissolved with the aid of sonication. The resulting solution was stirred at room temperature for 6 days. The solution was concentrated to remove most of DCM and the residue was added to a solution of 250 mL of diethyl ether and 5 mL of MeOH to precipitate out the activated PLA-NHS ester. The solvents were removed and the polymer was washed twice with ether (2×200 mL) and dried under vacuum to give PLA-NHS activated ester as a white foamy solid (˜8 g recovered, H NMR was used to confirm the presence of NHS ester). The PLA-NHS ester was stored under argon in a below −10 C freezer before use.

[0134]Alternatively, the reaction can be performed in DMF...

example 2

Preparation of Activated Polymer

[0136]PLA (R202H, acid number of 0.21 mmol / g) (2.0 g, 0.42 mmol, 1.0 eq) was dissolved in 10 mL of dry acetonitrile. N,N′-disuccinimidyl carbonate (DSC) (215 mg, 1.26 mmol, 3.0 eq) and catalytic amount of 4-(N,N-dimethylamino)pyridine (DMAP) were added. The resulting mixture was stirred under argon for 1 day. The resulting solution was concentrated to almost dryness. The residue was then added to 40 mL of ether to precipitate out the polymer which was washed twice with ether (2×30 mL) and dried under vacuum to give PLA-NHS activated ester (1H NMR showed the amount of NHS ester at about 80%).

example 3

Preparation of Activated Polymer

[0137]PLA (R202H) (5.0 g, 1.05 mmol) was dissolved in 25 mL of anhydrous DCM and 2.5 mL of anhydrous DMF. DCC (650 mg, 3.15 mmol, 5.0 eq) and pentafluorophenol (PFP) (580 mg, 3.15 mmol, 5.0 eq) were added. The resulting solution was stirred at room temperature for 6 days and then concentrated to remove DCM. The resulting residue was added to 250 mL of ether to precipitate out the activated PLA polymer which was washed with ether (2×100 mL) and dried under vacuum to give PLA-PFP activated ester as a white foamy solid (4.0 g).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weight average molecular weightaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

This invention relates to compositions, and related methods, of synthetic nanocarriers that comprise immunomodulatory agents and antigens that are differentially released from the synthetic nanocarriers.

Description

RELATED APPLICATIONS[0001]This application claims the benefit under 35 U.S.C. §119 of U.S. provisional applications 61 / 217,129, 61 / 217,117, 61 / 217,124, and 61 / 217,116, each filed May 27, 2009, the contents of each of which are incorporated herein by reference in their entirety.FIELD OF THE INVENTION[0002]This invention relates to compositions, and related methods, of synthetic nanocarriers that comprise immunomodulatory agents and antigens that are differentially released from the synthetic nanocarriers.BACKGROUND[0003]Common vaccination strategies include the administration of antigens with adjuvants. However, information regarding the biological interplay between these two agents and how the control of their delivery can provide for optimal in vivo effects is lacking. There is a need for new methods for delivering antigens with adjuvants that allow for optimal in vivo effects as well as related compositions.SUMMARY OF THE INVENTION[0004]Aspects of the invention relate to compositi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/385A61P37/02A61P31/00A61P35/00A61P3/00
CPCA61K31/437A61K31/52A61K39/0005C07D471/04C07D473/34C08G63/06C08G63/08C08G63/912C08G64/42C08J3/24A61K39/385A61K39/39B82Y5/00A61K9/5138A61K39/0013A61K2039/55561A61K2039/55555A61K2039/55544A61K2039/55511A61K2039/62A61K2039/6093A61K2039/627A61K39/00C08J2367/04A61K2300/00A61K47/60A61K47/58A61K47/59A61K47/593A61K47/64A61K47/6925A61K47/6935A61K47/6937A61P25/28A61P25/30A61P25/34A61P29/00A61P3/00A61P31/00A61P35/00A61P37/02A61P37/04A61P43/00A61K31/525C07D473/32
Inventor LIPFORD, GRAYSON B.ZEPP, CHARLESGAO, YUNKEEGAN, MARK J.BALDWIN, SAMFU, FEN-NIJOHNSTON, LLYOD
Owner SELECTA BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com